Jeffrey Stuart Peters - 22 Feb 2022 Form 4 Insider Report for MACROGENICS INC (MGNX)

Role
Senior VP and General Counsel
Signature
/s/ Lynn Cilinski, Attorney-in-Fact
Issuer symbol
MGNX
Transactions as of
22 Feb 2022
Net transactions value
$0
Form type
4
Filing time
24 Feb 2022, 18:48:14 UTC
Next filing
17 Feb 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Award $0 +70,000 $0.000000 70,000 22 Feb 2022 Common Stock 70,000 $10.15 Direct F1
transaction MGNX Restricted Stock Unit Award $0 +35,000 $0.000000 35,000 22 Feb 2022 Common Stock 35,000 $0.000000 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.
F2 Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock.
F3 The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant.